| A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. | |
| | |
MedLine Citation:
|
PMID: 20703455 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
HLA-mismatched natural killer (NK) cells have shown efficacy in acute myeloid leukemia, and their adoptive transfer in patients with other malignancies has been proven safe. This phase I clinical trial was designed to evaluate safety (primary endpoint) and possible clinical efficacy (secondary endpoint) of repetitive administrations of allogeneic, in vitro activated and expanded NK cells along with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Patients with unresectable, locally advanced/metastatic NSCLC receiving 1st/2nd line chemotherapy were eligible to receive 2-4 doses of activated NK cells from two relative donors. Donor's CD56(+) cells were cultured for 20-23 days with interleukin-15 (IL-15) and hydrocortisone (HC) and administered intravenously between chemotherapy cycles. Premedication with corticosteroids and/or H1 inhibitors was allowed. Sixteen patients (performance status 0-1) with adenocarcinoma (n = 13) or squamous cell carcinoma (n = 3) at stage IIIb (n = 5) or IV (n = 11) receiving 1st (n = 13) or 2nd (n = 3) line treatment were enrolled. Fifteen patients received 2-4 doses of allogeneic activated NK cells (0.2-29 × 10(6)/kg/dose, median 4.15 × 10(6)/kg/dose). No side effects (local or systemic) were observed. At a median 22-month follow-up (range, 16.5-26 months) 2 patients with partial response and 6 patients with disease stabilization were recorded. Median progression free survival and overall survival were 5.5 and 15 months, respectively. A 56% 1-year survival and a 19% 2-year survival were recorded. In conclusion, repetitive infusions of allogeneic, in vitro activated and expanded with IL-15/HC NK cells, in combination with chemotherapy are safe and potentially clinically effective. |
| | |
Authors:
|
Eleni G Iliopoulou; Panteleimon Kountourakis; Michalis V Karamouzis; Dimitrios Doufexis; Alexandros Ardavanis; Constantin N Baxevanis; Gerasimos Rigatos; Michael Papamichail; Sonia A Perez |
Related Documents
:
|
11891025 - A randomized trial of systematic nodal dissection in resectable non-small cell lung can... 12833465 - Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable stag... 20974565 - Seom clinical guidelines for the treatment of non-small-cell lung cancer: an updated ed... 17851225 - Mdr1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy... 23213075 - Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in ac... 11406035 - Palliative radiotherapy regimens for non-small cell lung cancer. |
Publication Detail:
|
Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-08-12 |
Journal Detail:
|
Title: Cancer immunology, immunotherapy : CII Volume: 59 ISSN: 1432-0851 ISO Abbreviation: Cancer Immunol. Immunother. Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-09-27 Completed Date: 2010-10-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8605732 Medline TA: Cancer Immunol Immunother Country: Germany |
Other Details:
|
Languages: eng Pagination: 1781-9 Citation Subset: IM |
Affiliation:
|
Cancer Immunology and Immunotherapy Center, Saint Savas Cancer Hospital, 171 Alexandras Avenue, 115 22, Athens, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adoptive Transfer*
/
adverse effects Aged Carcinoma, Non-Small-Cell Lung / mortality, therapy* Female Humans Immunotherapy K562 Cells Killer Cells, Natural / immunology* Lung Neoplasms / mortality, therapy* Male Middle Aged |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Respiratory variation in aortic blood flow velocity as a predictor of fluid responsiveness in childr...
Next Document: Posterior-only surgery with strong halo-femoral traction for the treatment of adolescent idiopathic ...